Phase 1 recruiting for a new imaging tracer: 61Cu-NODAGA-PSMA

[Maxone73]

A Phase I clinical trial is testing 61Cu-NODAGA-PSMA, a new molecular imaging radiotracer for prostate cancer. This compound targets PSMA, a protein on prostate cancer cells, and uses Copper-61 (61Cu), which has a longer half-life (3.3 hours) compared to conventional isotopes like Fluorine-18 or Gallium-68, allowing for broader distribution.

The trial will enroll 8 participants with PSMA-positive prostate cancer and aims to evaluate the safety of 61Cu-NODAGA-PSMA and its ability to detect cancerous lesions. Secondary objectives include dosimetry and comparing its performance with standard 18F-Piflufolastat PET/CT scans. If successful, this innovative radiotracer could progress to Phase II trials and improve accessibility to advanced prostate cancer imaging.

prostatewarriors.com/2024/1...

[petabyte]

Interesting as always. The source link is even more positive (from the company promoting it ofc) about the potential.

I suppose imaging trials will progress faster than drug trials?

[Maxone73 in reply to petabyte]

Yes, but my feeling is that they are all pointing to theranostics, like Clarity with 64Cu and 67Cu